MwanzoAVDL • NASDAQ
add
Avadel Pharmaceuticals PLC
$ 11.66
Baada ya Saa za Kazi:(0.00%)0.00
$ 11.66
Imefungwa: 22 Nov, 20:00:00 GMT -5 · USD · NASDAQ · Kanusho
Bei iliyotangulia
$ 11.66
Bei za siku
$ 11.53 - $ 12.22
Bei za mwaka
$ 10.41 - $ 19.09
Thamani ya kampuni katika soko
1.12B USD
Wastani wa hisa zilizouzwa
1.35M
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 50.02M | 613.22% |
Matumizi ya uendeshaji wa biashara | 44.20M | 5.21% |
Mapato halisi | -2.62M | 92.76% |
Kiwango cha faida halisi | -5.25 | 98.98% |
Mapato kwa kila hisa | -0.03 | 92.68% |
EBITDA | elfu 708.00 | 102.05% |
Asilimia ya kodi ya mapato | -3.47% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 65.81M | -57.04% |
Jumla ya mali | 158.25M | -22.08% |
Jumla ya dhima | 83.59M | -10.07% |
Jumla ya hisa | 74.66M | — |
hisa zilizosalia | 96.36M | — |
Uwiano wa bei na thamani | 14.95 | — |
Faida inayotokana na mali | -0.52% | — |
Faida inayotokana mtaji | -0.73% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -2.62M | 92.76% |
Pesa kutokana na shughuli | -6.89M | 81.98% |
Pesa kutokana na uwekezaji | 4.93M | -49.80% |
Pesa kutokana na ufadhili | 1.18M | -96.14% |
Mabadiliko halisi ya pesa taslimu | elfu -265.00 | -114.51% |
Mtiririko huru wa pesa | -9.99M | 64.96% |
Kuhusu
Avadel Pharmaceuticals plc, is a specialty pharmaceutical company. Avadel markets products in the hospital and primary care spaces. The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France.
The company was founded as Flamel Technologies SA in Lyon, France in 1990.
The company acquired Éclat Pharmaceuticals of St. Louis, Missouri in March 2012.
On 8 February 2016, the company acquired FSC Holdings, LLC, which included its wholly owned subsidiaries FSC Pediatrics, Inc., FSC Therapeutics, LLC, and FSC Laboratories, Inc.
On 3 January 2017, Flamel, Éclat, and FCS Pediatrics became Avadel Pharmaceuticals plc after the Company completed a cross-border merger from France to Ireland.
In 2019, Mike Anderson, CEO of Avadel Pharmaceuticals has resigned, and Gregory Divis, COO of the company was appointed as his temporary successor. Meanwhile, Craig Stapleton, chairman of the Dublin-headquartered Avadel, has also stepped down. That same year, the company filed for Chapter 11 bankruptcy.
In May 2023, Avadel Pharmaceuticals received FDA approval for Lumryz, an extended-release oral suspension of sodium oxybate. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
1990
Tovuti
Wafanyakazi
154
